These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 11196383)

  • 1. [Deletion of ABH antigens in urine sediment cells from patients with prostatic adenoma].
    Foresto P; Biondi C; Brufman A; Yaber F; Yaber F; Solis E; Provenzal O; Valverde J
    Arch Esp Urol; 2000 Nov; 53(9):770-3. PubMed ID: 11196383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Abnormal glycosylation of soluble ABH antigens in tumors of the urinary tract].
    Foresto P; Bioindi C; Racca L; Brufman A; Yaber F; Solis E; Provenzal O; Valverde J
    Arch Esp Urol; 2000 Apr; 53(3):196-9. PubMed ID: 10851724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
    Zhao Z; Liu J; Li S; Shen W
    Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer.
    Hillenbrand M; Bastian M; Steiner M; Zingler C; Müller M; Wolff JM; Seiter H; Schuff-Werner P
    Anticancer Res; 2000; 20(6D):4995-6. PubMed ID: 11326656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The association of prostate stem cell antigen (PSCA) mRNA expression and subsequent prostate cancer risk in men with benign prostatic hyperplasia following transurethral resection of the prostate.
    Zhigang Z; Wenlu S
    Prostate; 2008 Feb; 68(2):190-9. PubMed ID: 18076024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of medical therapy on surgery for benign prostatic hyperplasia: a study comparing changes in a decade (1992-2002).
    Vela-Navarrete R; Gonzalez-Enguita C; Garcia-Cardoso JV; Manzarbeitia F; Sarasa-Corral JL; Granizo JJ
    BJU Int; 2005 Nov; 96(7):1045-8. PubMed ID: 16225526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postoperative PSA and PSA velocity identify presence of prostate cancer after various surgical interventions for benign prostatic hyperplasia.
    Helfand BT; Anderson CB; Fought A; Kim DY; Vyas A; McVary KT
    Urology; 2009 Jul; 74(1):177-83. PubMed ID: 19428074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Highly specific detection of prostate-specific antigen-positive cells in the blood of patients with prostate cancer or benign prostatic hyperplasia, using a real-time reverse-transcription-polymerase chain reaction method with improved sensitivity.
    Barbero G; Destefanis P; Procida S; Mandili G; Ulliers D; Ceruti C; Fiori C; Maule MM; Fontana D; Giribaldi G; Turrini F
    BJU Int; 2008 Dec; 102(11):1566-72. PubMed ID: 18549428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of prostate-specific antigen level and prostate volume as predictors of efficacy in photoselective vaporization prostatectomy: analysis and results of an ongoing prospective multicentre study at 3 years.
    Te AE; Malloy TR; Stein BS; Ulchaker JC; Nseyo UO; Hai MA
    BJU Int; 2006 Jun; 97(6):1229-33. PubMed ID: 16686717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic stress responses in patients undergoing surgery for benign prostatic hyperplasia.
    Ruzic B; Tomaskovic I; Trnski D; Kraus O; Bekavac-Beslin M; Vrkic N
    BJU Int; 2005 Jan; 95(1):77-80. PubMed ID: 15638899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A comparative study on different doses of cernilton for preventing the clinical progression of benign prostatic hyperplasia].
    Xu J; Qian WQ; Song JD
    Zhonghua Nan Ke Xue; 2008 Jun; 14(6):533-7. PubMed ID: 18649754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circadian rhythm of blood pressure in patients with benign prostatic hyperplasia.
    Turgut F; Bayrak O; Kanbay M; Ozkara A; Uz E; Bavbek N; Kargili A; Akcay A
    Scand J Urol Nephrol; 2008; 42(1):47-52. PubMed ID: 17853012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of high-energy transurethral microwave thermotherapy in alleviating medically refractory urinary retention due to benign prostatic hyperplasia.
    Kellner DS; Armenakas NA; Brodherson M; Heyman J; Fracchia JA
    Urology; 2004 Oct; 64(4):703-6. PubMed ID: 15491705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
    Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
    Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Whole blood selenium levels (WBSL) in patients with prostate cancer (PC), benign prostatic hyperplasia (BPH) and healthy male inhabitants (HMI) and prostatic tissue selenium levels (PTSL) in patients with PC and BPH.
    Muecke R; Klotz T; Giedl J; Buentzel J; Kundt G; Kisters K; Prott FJ; Micke O
    Acta Oncol; 2009; 48(3):452-6. PubMed ID: 18855158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study.
    McNeill SA; Hargreave TB; Roehrborn CG;
    Urology; 2005 Jan; 65(1):83-9; discussion 89-90. PubMed ID: 15667868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study.
    Roehrborn CG
    BJU Int; 2006 Apr; 97(4):734-41. PubMed ID: 16536764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term results of medical treatment in benign prostatic hyperplasia.
    Kim CI; Chang HS; Kim BK; Park CH
    Urology; 2006 Nov; 68(5):1015-9. PubMed ID: 17095071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study.
    Yang Y; Zhao XF; Li HZ; Wang W; Zhang Y; Xiao H; Zhang X
    Chin Med J (Engl); 2007 Mar; 120(5):370-4. PubMed ID: 17376305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.